165 related articles for article (PubMed ID: 28143714)
1. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling.
Nikolova T; Roos WP; Krämer OH; Strik HM; Kaina B
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):29-39. PubMed ID: 28143714
[TBL] [Abstract][Full Text] [Related]
2. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Kaina B; Christmann M
DNA Repair (Amst); 2019 Jun; 78():128-141. PubMed ID: 31039537
[TBL] [Abstract][Full Text] [Related]
3. Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.
Berte N; Piée-Staffa A; Piecha N; Wang M; Borgmann K; Kaina B; Nikolova T
Mol Cancer Ther; 2016 Nov; 15(11):2665-2678. PubMed ID: 27474153
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.
Batista LF; Roos WP; Christmann M; Menck CF; Kaina B
Cancer Res; 2007 Dec; 67(24):11886-95. PubMed ID: 18089819
[TBL] [Abstract][Full Text] [Related]
5. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
7. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
Roos WP; Tsaalbi-Shtylik A; Tsaryk R; Güvercin F; de Wind N; Kaina B
Mol Pharmacol; 2009 Oct; 76(4):927-34. PubMed ID: 19641035
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
9. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
10. Specific DNA repair mechanisms may protect some human tumor cells from DNA interstrand crosslinking by chloroethylnitrosoureas but not from crosslinking by other anti-tumor alkylating agents.
Gibson NW; Zlotogorski C; Erickson LC
Carcinogenesis; 1985 Mar; 6(3):445-50. PubMed ID: 3978757
[TBL] [Abstract][Full Text] [Related]
11. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.
Christmann M; Verbeek B; Roos WP; Kaina B
Biochim Biophys Acta; 2011 Dec; 1816(2):179-90. PubMed ID: 21745538
[TBL] [Abstract][Full Text] [Related]
12. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Passagne I; Evrard A; Depeille P; Cuq P; Cupissol D; Vian L
Toxicol Appl Pharmacol; 2006 Mar; 211(2):97-105. PubMed ID: 16039682
[TBL] [Abstract][Full Text] [Related]
13. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
Kaina B; Christmann M; Naumann S; Roos WP
DNA Repair (Amst); 2007 Aug; 6(8):1079-99. PubMed ID: 17485253
[TBL] [Abstract][Full Text] [Related]
14. Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
Tomaszowski KH; Schirrmacher R; Kaina B
Mol Pharm; 2015 Nov; 12(11):3924-34. PubMed ID: 26379107
[TBL] [Abstract][Full Text] [Related]
15. Focus on Fotemustine.
De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone.
Zlotogorski C; Erickson LC
Carcinogenesis; 1983; 4(6):759-63. PubMed ID: 6861280
[TBL] [Abstract][Full Text] [Related]
18. The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy.
Guohui S; Lijiao Z; Rugang Z
Anticancer Agents Med Chem; 2015; 16(2):221-46. PubMed ID: 26299659
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Passagne I; Evrard A; Winum JY; Depeille P; Cuq P; Montero JL; Cupissol D; Vian L
J Pharmacol Exp Ther; 2003 Nov; 307(2):816-23. PubMed ID: 12970393
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
